Thermo Fisher Scientific Inc. $TMO Shares Sold by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,900 shares of the medical research company’s stock after selling 700 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Thermo Fisher Scientific were worth $8,069,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in TMO. CBIZ Investment Advisory Services LLC increased its position in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after acquiring an additional 33 shares during the last quarter. Anderson Financial Strategies LLC acquired a new stake in Thermo Fisher Scientific during the 1st quarter valued at approximately $30,000. Keystone Global Partners LLC acquired a new stake in Thermo Fisher Scientific during the 1st quarter valued at approximately $31,000. IMA Advisory Services Inc. purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at approximately $35,000. Finally, Smallwood Wealth Investment Management LLC purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at approximately $37,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company’s stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,066 shares of company stock valued at $14,182,963. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $539.54 on Wednesday. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The firm has a market capitalization of $203.73 billion, a P/E ratio of 31.21, a PEG ratio of 2.95 and a beta of 0.77. The firm’s 50 day moving average is $484.90 and its two-hundred day moving average is $447.60. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same period in the prior year, the company posted $5.37 EPS. The business’s revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is currently 9.95%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a report on Thursday, July 24th. William Blair started coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an “outperform” rating for the company. HSBC reiterated a “hold” rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Finally, Robert W. Baird increased their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $591.16.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.